Clinical outcome after front-line intensive sequential chemotherapy (ISC) in patients with aggressive non-Hodgkin's lymphoma and high-risk international prognostic index (IPI 3): final analysis of survival in two consecutive ISC trials.
暂无分享,去创建一个
R. Bouabdallah | D. Blaise | D. Coso | C. Chabannon | V. Bardou | D. Maraninchi | A. Stoppa | J. Gastaut